Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sertraline versus imipramine to prevent relapse in chronic depression
Autore:
Koran, LM; Gelenberg, AJ; Kornstein, SG; Howland, RH; Friedman, RA; DeBattista, C; Klein, D; Kocsis, JH; Schatzberg, AF; Thase, ME; Rush, AJ; Hirschfeld, RMA; LaVange, LM; Keller, MB;
Indirizzi:
Stanford Univ, Med Ctr, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 Univ, Med Ctr, Stanford, CA 94305 USA Univ Arizona, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721Univ Arizona, Tucson, AZ 85721 USA Virginia Commonwealth Univ, Richmond, VA 23284 USA Virginia Commonwealth Univ Richmond VA USA 23284 , Richmond, VA 23284 USA Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA Univ Pittsburgh Pittsburgh PA USA 15260 Med Ctr, Pittsburgh, PA 15260 USA Cornell Univ, Med Ctr, Ithaca, NY 14853 USA Cornell Univ Ithaca NY USA 14853 nell Univ, Med Ctr, Ithaca, NY 14853 USA SUNY Stony Brook, Stony Brook, NY 11794 USA SUNY Stony Brook Stony Brook NY USA 11794 rook, Stony Brook, NY 11794 USA Univ Texas, SW Med Ctr, Dallas, TX 75230 USA Univ Texas Dallas TX USA 75230 iv Texas, SW Med Ctr, Dallas, TX 75230 USA Univ Texas, Med Branch, Galveston, TX 77550 USA Univ Texas Galveston TX USA 77550 as, Med Branch, Galveston, TX 77550 USA Quintiles Inc, Dept Biostat, Res Triangle Pk, NC USA Quintiles Inc Res Triangle Pk NC USA pt Biostat, Res Triangle Pk, NC USA Brown Univ, Butler Hosp, Providence, RI 02912 USA Brown Univ Providence RI USA 02912 Butler Hosp, Providence, RI 02912 USA
Titolo Testata:
JOURNAL OF AFFECTIVE DISORDERS
fascicolo: 1, volume: 65, anno: 2001,
pagine: 27 - 36
SICI:
0165-0327(200106)65:1<27:SVITPR>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRICYCLIC ANTIDEPRESSANTS; MAJOR DEPRESSION; CLINICAL-TRIAL; FOLLOW-UP; PLACEBO; CONTINUATION; DYSTHYMIA; EFFICACY; THERAPY; UNDERTREATMENT;
Keywords:
chronic depression; dysthymia; sertraline; imipramine; continuation phase treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Koran, LM OCD Clin, Room 2363,401 Quarry Rd, Stanford, CA 94305 USA OCD Clin Room 2363,401 Quarry Rd Stanford CA USA 94305 94305 USA
Citazione:
L.M. Koran et al., "Sertraline versus imipramine to prevent relapse in chronic depression", J AFFECT D, 65(1), 2001, pp. 27-36

Abstract

Background: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. Methods. After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-centertrial of sertraline or imipramine. patients with chronic depression ( greater than or equal to 2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially. 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. Results: Of 239 acute or crossover responders to sertraline. 60% entered continuation in full remission and 40% with a partial remission. These proportions were identical for imipramine patients (n = 147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40% achieved full remission. patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. Limitations: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. Conclusions: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patientswith a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects. but both drugs were well tolerated. (C)2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 16:18:10